viewAmryt Pharma PLC

Amryt Pharma granted US patent for lead drug

Children with this disorder are frequently referred to as "Butterfly Children"

picture of patent document
Amryt will now move onto phase III trial

Amryt Pharma has been granted a US patent for its lead drug, Episalvan, a treatment for Epidermolysis Bullosa (EB).  a rare, hereditary skin disorder.

The most serious cases lead to disfigurement and cause intense suffering. 

Children with this disorder are frequently referred to as "Butterfly Children". 

Episalvan has already shown faster healing for wounds and chronic wounds compared to standard care and Amryt (LON:AMYT)  is now preparing a phase III trial for the drug's use in EB treatment.

Europe’s medicines agency granted Episalvan a patent for the treatment of all partial thickness wounds in January.

Amryt estimates that the global EB market is worth US$1.5bn per annum.

Joe Wiley, chief executive, said he hoped the phase III trial for the use of Episalvan in EB treatment would start in the first quarter of 2017.

A meeting of the US Food and Drug Administration is planned for early in the next quarter to establish the trial’s study protocol. A clinical research organisation has been identified to conduct the phase III study.

A US application has also been made for orphan designation for AP102, a treatment for excess growth hormone condition acromegaly, with a pre-clinical study to be completed in coming weeks.

Amryt, which reversed into oil and gas group Fastnet in April, has cash of €10.7mln and posted a loss of €4.1mln in the half year to June.

Quick facts: Amryt Pharma PLC

Price: 182.5 GBX

Market: AIM
Market Cap: £281.96 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...



Orphan drug status for new compound 'great news' says Amryt Pharma PLC's COO

Amryt Pharma PLC (LON:AMYT) has been granted orphan drug status in the US for  a compound called AP102 to treat patients with the excess growth condition acromegaly. Chief operating officer Rory Nealon tells Proactive: ''Our focus is to acquire, develop and commercialise products in the...

on 11/07/2016

2 min read